Evaluation of the Pharmacokinetics, Safety and Tolerability of a Single Dose of GLPG3067 Administered as Solid Formulation in Male Subjects With Cystic Fibrosis.
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Navocaftor (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Galapagos NV
- 23 Jul 2018 New trial record